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Abstract 
Diabetes mellitus(DM) is a major worldwide  health problem leading to markedly increase mortality and serious 
morbidity. Immunological disturbances involving the cell mediated immune system and improper T-lymphocyte 
function also contribute to the path physiology of type 2 DM.It has been reported that ADA,IL-6,and TNF-α 
levels  were a good marker for immunological disturbance in type 2 DM  patients.This study aims to assess and 
compare the level of serum ADA, IL-6 ,and TNF-α in patient of type 2 DM with and without oral hypoglycamic 
drugs.The study population consist of 150 subjects divided in to 3 groups:group I (50normal health 
controls),group II (45 type 2 DM patients with no on hypoglycemic drugs),and group Ш (55 type 2 DM patients 
on hypoglycemic drugs).There were a significant(p<0.001) tremendous increase in ADA,IL-6,and TNF-α levels 
(47.32 U/L ,29.04 pg/ml ,and 98.23 pg/ml, respectively ) in group II  than group I and group Ш. also, ADA,IL-
6,and TNF-α levels were significantly(p<0.001) higher in group Ш than group I.As conclusion ,the increase in 
ADA,IL-6,and TNF-α levels  is a good glycemic  markers associated with type 2 DM .The intake of 
hypoglycaemic drugs  decrease the levels of these markers.   
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1.Introduction 
Diabetes mellitus is the major health problem affecting both developed and developing countries, its a group of 
metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or 
both(Bobb etal.2008).The chronic hyperglycemia of diabetes is associated with long-term dysfunction, damage, 
and failure of various organs, especially the eyes,kidneys,nerves, heart, and blood vessels(Li et al.,2011).  
Type 2 diabetes mellitus, the most prevalent form of the disease, is often asymptomatic in its early stages and 
can remain undiagnosed for many years. Individuals with undiagnosed type 2 diabetes are also at significantly 
higher risk for stroke, coronary heart disease, and peripheral  vascular disease than the non diabetic 
population(ADA,2008).Insulin resistance and impaired insulin secretion are the main physiological 
abnormalities associated with T2DM (Khemka et al.,2013). Immunological disturbances involving the cell 
mediated immune system and improper T-lymphocyte function also contribute to the pathophysiology of T2DM 
(Prakash et al.2006) 
Adenosine deaminase (ADA), an enzyme presents in red cells and the vessel wall catalyses the irreversible 
hydrolytic deamination of adenosine to inosine and 2’- deoxyadenosine to 2’-deoxyinosine.Both inosine and 2’-
deoxyinosine are converted to hypoxanthine, xanthine and finally to uric acid (UA. The enzyme exists in two 
isoenzyme forms:(ADA1 and ADA2) which are coded by separate genes (Gakis,1996). ADA is considered as a 
good marker of cell mediated immunity. Adenosine is a suppressant of inflammation;effectively inhibit T-cell 
activation and proliferation.Increased level of ADA decreases adenosine concentration.Increased ADA indicates 
increased inflammatory state of a cell Its play a crucial role in lymphocyte proliferation and differentiation and 
its shows its highest activity in T-lymphocytes (Sullivan et al.,1977).High lymphocyte ADA activities were 
found to be elevated in diseases in which there is a cell mediated immune response (Prakash et al.2006). 
Adenosine deaminase (ADA) is an enzyme that has been suggested to be important for modulating the 
bioactivity of insulin (1) Chronic hyperglycemia leads to increased oxidative stress by forming enediol radicals 
and superoxide ions by NADPH oxidase system and increases ADA levels, both leading to insulin 
resistance(Singh et al ,2013).  
Individuals who progress to type 2 diabetes display features of low-grade inflammation years in advance of 
disease onset.This low-grade inflammation has been proposed to be involved in the pathogenetic processes 
causing type 2 diabetes.Mediators of inflammation such as tumor necrosis factor, interleukin ,IL-6, IL-18,and 
certain chemokines have been proposed to be involved in the events causing both forms of diabetes. IL-6 has in 
addition to its immunoregulatory actions been proposed to affect glucose homeostasis and metabolism directly 
and indirectly by action on skeletal muscle cells,adipocytes, hepatocytes,pancreatic-cells, and neuroendocrine 
cells (Kristiansen and Mandrup-poulsen,2005). 
Concentrations of acute-phase response markers and mediators of inflammation such as cytokines like TNF-α 
and IL-6 are also raised in people with T2DM. This finding has led to the suggestion that raised concentrations 
of pro-inflammatory cytokines and the resultant acute-phase response may underlie much of the metabolic 
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clustering due to diabetes mellitus(Hotanisligil et al.,1994). cytokines operate as a network in stimulating the 
production of acute-phase proteins. Obesity, as well as hyperglycemia, contributes to the rise of these 
inflammatory markers(Goyal, et al.2015). 
 The present study was undertaken to assess and compare level  of serum ADA activity and serum IL-6 and 
TNF-α in patients with  type 2 diabetes mellitus with and without treatment in order to use it as a marker  of  
immunological disturbances in T2DM patients. 
2. Materials and Methods 
The subject included in the present study were 100 patients of type2 DM (55 of them on oral hypoglycaemic   
drugs and 45 of them without on any hypoglycemic drugs) with age group of 25-60 years of either sex. A group 
of 50 normal healthy individuals ,who were age and sex match with patients group.the study group and control 
were selected from patient and healthy  individuals visiting  the clinical lab.of AL-Sadder Medical City in Najaf/ 
Iraq during the period 2015. Five ml of venous blood were collected from patients and control by vein puncture 
and allowed to clot at room temperature for 30 min.then centerfuged for 20 minutes at approximately 1,000 x 
g.and then The serum separated for ADA ,IL-6,TNF-α level detection. These 150 subjects were divided into 
three groups: 
Group I:Comprised of 50 normal healthy individuals as control group. 
Group II:Comprised of 45patients of types 2 DM without hypoglycaemic drugs.   
Group III:Comprised of 55 patients of types 2 DM on hypoglycaemic drugs.  
Inclusion Criteria: All clinically diagnosed cases of type 2 DM were included in the study was based on 2010 
American diabetic associated criteria (27) many patients with history of type 2 DM for more than 1 years were 
included the study. 
2.1 Exlusion Criteria 
Patients with type 2 DM with any other chronic disease such as renal failure,Rheumatoid arthritis,tuber culossis, 
and patients with type 2 DM on insulin treatment, to minimize possible confounding of results. 
The total level of serum ADA was measured by end point colorimetic method by commercially supplied Kit 
(Tulip Diagnostic).the assay was based on the colorimetric method described by Gusti and Galanti (Guisti,1974). 
The concentration of TNF-α and IL-6 in serum samples of type 2 DM and healthy controls were done by use of a 
commercial ELISA Kit (Orenium Laboratory,Finland).The interassay and intra coefficients of variation for IL-6 
were 9.4 % and 8.8 % and for TNF-α were 5.2% and 7.4%. 
2.2 Statically analysis 
The results obtained from this study were expressed as mean± SD by using Excel  2007.Ttest was done to 
compare ADA,TNF-α ,and IL-6 between three groups by using SPSS Software, Version 16. 
3. Results and Discussion 
In the present study,the mean serum ADA level of group II (patients of type 2 DM without any hypoglycaemic 
drugs) were significantly higher (P< 0.001 ) than group I (control group) and group III (patients of type 2 DM on 
oral hypoglycaemic drugs).Also, the level of ADA were significantly higher in group III (30.05) U/L than group 
I(18.20) U/L (Table 1). 
Diabetes mellitus,a common endocrine metabolic disorder, is a leading cause of death worldwide. It is 
characterized by hyperglycemia resulting from a variable interaction of hereditary and environmentalfactors and 
is due to the combination of insulin resistance (impairment in insulin-mediated glucose disposal) and defective 
secretion of insulin by pancreatic β cells (WHO,2014). 
In the present study, patients of type 2 DM (group I and group Ш)appeared high level of ADA than normal 
healthy control. Similar results were reported by Hoshino et al.,(1994), Kurtol et al.,(2004), Kaur et al., (2012), 
and   Singh et al., (2013). All these study reported elevated ADA level in serum of type 2 DM patient whereas 
Angielski et al., (1989) demonstrated that ADA activety were not change in isolated glomeruli of Streptozocin 
diabetic rats. Ramani  et al.,(2012) depleted that ADA activity in type 2 DM patients was significant highes than 
in the control group(mean ± SD of 32.06 ± 17.09 v. 19.28 ± 5.59, p< 0.001). Shantaram et al.(2014).found that 
ADA level were decreased in the patients of type 2 DM as compared to controls. And they found that the 
decrease in ADA level may be due to the depressed cell mediated immunity in the patients due to intake of 
medicines to control their blood sugar. 
ADA plays a crucial role in lymphocyte proliferation and differentiation , and shows its highest activity in T-
lymphocytes . In the present study, a significant elevation in the ADA levels was observed in diabetic subjects 
compared to the controls. High plasma ADA activity might be due to abnormal Tlymphocyte responses or 
proliferation and may point to a mechanism that involves its release into circulation (Ankush et 
al.,2009).Therefore, as presented in Table (1), increased ADA activity in diabetic individuals could be due to 
altered insulin related  T-lymphocyte function (Kumar et al.,2008). 
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Insulin resistance and impaired insulin secretion are the main physiological abnormalities associated with T2DM 
.Adenosine is responsible for increasing glucose uptake into cells.Thus, higher ADA activity in insulin sensitive 
tissue will decrease adenosine levels which in turn decrease glucose uptake into cells.ADA also plays a crucial 
role in lymphocyte proliferation and differentiation and is highly active in T-lymphocytes (Zavialov et 
al.,2010).Thus, a suppression of ADA activity may help improve insulin sensitivity and inflammation,cell 
proliferation, and T-lymphocyte activity,all of which are putatively associated with the pathophysiology of 
T2DM.  
  In other words,Adenosine mimics the action of insulin on glucose and lipid metabolism in adipose tissue and 
the myocardium, while it inhibits the effect of insulin on total hepatic glucose output, which suggests that 
adenosine, causes local insulin resistance in the liver. Adenosine modulates the action of insulin on various 
tissues differently and its concentration in tissues is affected by ADA level (Warrier et al., 1995). 
In this study, anegligible level of TNF-α (5.22 pg/ml) and IL-6 pg/ml) was recorded in group I (normal healthy 
control).Sample of group III (type 2 DM patient without any hypoglycaemic  drugs) showed an  significant (p< 
0.001) augmentation in the level TNF-α (24.7 pg/ml) and IL-6 12-4 pg/ml),respectively.A tremendous 
augmentation was observe in the level of TNF-α (98.23 pg/ml),p< 0.001) and IL-6 (29.04 pg/ml) in group II 
(type 2 DM patients on oral hypoglycemic drug). 
The result of this study compatible with Goyal et al,2015) when they reported an increase of TNF-α and  IL-6 
level in DM patients and increase was more in obese than nonobes diabetics), and also, they found that insulin 
induced down regulation of  TNF-α and  IL-6 in nonobes and obese diabetical patients. 
Ahmed (2005) and Goldsby et al.,(2008) reported that   Hyperglycaemia causes formation of Advanced 
glycation End Products (AGEs).The AGEs stimulate receptors for advanced glycation end products (RAGE).In 
addition they increase the generation of reactive oxygen species in macrophages thereby causing heightened 
oxidative stress. AGEs bind to AGE receptors on several cell types (endothelial cells, mesangial cells and 
macrophages) lead to release of cytokines; TNF-α, IL-1,IL-6 and growth factor from macrophages and 
mesangial cells  resulting in activation of T lymphocytes.Furthermore, in the presence of superoxide dismutase, 
superoxide anion leads to formation of H2O2 which is responsible for activating the signalling molecules leading 
to inflammation (Singh et al., 2009).In addition,A close correlation has been found between the severity of 
inflammation and a local increase in both expression and activity of ADA (Kaur et al.,2012). 
TNFa and IL-6 are the major cytokines produced by adipose tissue and their circulating levels are increased in 
diabetics(Rajarajeswari et al.,2011).Elevated  levels of IL-6, which is the main stimulator of the production of 
most acute-phase proteins,increase the risk of diabetes(Pradhan et al.,2001).Goyal et al. (2015) found that 
insulin-induced down regulation of TNF-α and IL-6 in nonobese and obese diabetic patients. Therefore, we 
concluded that elevated adenosine deaminase  and pro-inflamatory cytokines(TNF-α and IL-6 ) my be an 
important indicator in the immunopathogenic of type 2 diabetes mellitus . 
 
Table 1.Comparison of serum Adenosine Deaminase (ADA) levels in three groups 
Group Number Mean ± SD ( U/L) Comparison P value 
I 50 18.20 ± 6.21      I  vs. II P< 0.001 
II 45 47.32 ± 8.79 I  vs.  III P< 0.001 
III 55 30.05 ± 12.14 II  vs.  III P< 0.001 
 
Table 2.Comparesion of TNF-α and IL-6 level in three groups 
Group TNF-α   (pg/ml) IL-6   (pg/ml) 
I 5.32 ± 1.50 6.64 ± 1.23 
II 98.23 ±  3.2 29.04 ± 1.0 
III 24.7 ± 1.45 12.4 ± 2.8 
P value P< 0.001 P< 0.001 
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